What is the efficacy of interferon alfa (IFN-a) therapy in treating hepatitis B (HBV) (Hep B)-related glomerulonephritis?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

IFN-a therapy has been successful in treating HBV-related glomerulonephritis. A regimen of 5 million units of IFN-a subcutaneously (SC) daily for 4 months has achieved HBsAg seroconversion with improvement of glomerulonephritis. It has also been reported that IFN-a given at a dose of 3 million units 3 times per week led to an improvement of proteinuria only in patients with mesangial proliferative glomerulonephritis, not in those with membranoproliferative glomerulonephritis (MPGN).

Finally, a single case report described the resolution of this complication after liver transplantation. In addition to interferon, antiviral therapy with lamivudine (3TC) has not only been shown to significantly increase the incidences of proteinuria remission and of HBeAg seroconversion but also cause a decline in the levels of HBV-DNA in adult patients with HBV-related glomerulonephritis relative to controls. [69]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!